NICE issues final guidance on NHS use of Bayer’s Vitrakvi
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read Moreby Selina McKee | May 27, 2020 | News | 0
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read Moreby Selina McKee | Apr 22, 2020 | News | 0
The drug was initially considered too expensive but its cost to the NHS has been lowered
Read Moreby Anna Smith | Jan 17, 2020 | News | 0
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
Read Moreby Selina McKee | Sep 23, 2019 | News | 0
European regulators have cleared Bayer’s Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.
Read Moreby Anna Smith | Jan 8, 2019 | News | 0
Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8 billion.
Read Moreby Selina McKee | Nov 27, 2018 | News | 0
Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
